Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Shares Rise 17.4 Percent to Stop Recent Slide

Shares in Stratagene rose 17.4 percent for the trading week ended Tuesday, a few days after the firm’s shares hit a 52-week low of $3.98. The firm announced a licensing deal for bladder cancer test technology on Friday (see related article). But Stratagene’s shares rose 28 percent on Tuesday alone, after the company announced that its Universal Reference RNA was one of two reference standards selected as part of the US Food and Drug Administration’s MicroArray Quality Control Project, which published results this past week.
 
Only five firms in the BCW Index lost value for the tracking period. Molecular Devices led that group with a 3.3-percent drop in its stock, followed by a 3-percent decline for Millipore.
 
Overall, the Index rose .5 percent. In comparison, the Dow Jones Industrial Average gained .3 percent, the Nasdaq rose .5 percent, and the Nasdaq Biotech Index slipped 1.8 percent.
 
 


BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Current Price
(September 12, 2006)
Last Price
(September 5, 2006)
% change
Agilent
A
31.50
31.57
-0.2
Applied Biosystems
ABI
33.15
31.64
4.8
Beckman
BEC
55.26
54.50
1.4
Bio-Rad
BIO
71.59
73.47
-2.6
Bruker
BRKR
7.21
7.11
1.4
Fisher Scientific
FSH
78.20
77.86
0.4
GE
GE
34.67
33.97
2.1
Invitrogen
IVGN
63.34
61.38
3.2
Millipore
MIL
62.70
64.67
-3.0
Molecular Devices
MDCC
23.51
24.31
-3.3
PerkinElmer
PKI
18.69
18.31
2.1
Qiagen
QGEN
14.21
14.61
-2.7
Sigma
SIAL
73.20
72.97
0.3
Stratagene
STGN
5.52
4.70
17.4
Thermo
TMO
39.30
39.18
0.3
Waters
WAT
44.10
42.73
3.2
BCW Index Average
41.01
40.81
0.5